p-AKT Expression on Clinical Outcomes in Malignant Lymphoma

Completed

• Conditions: Malignant Lymphoma; P13K-AKT Pathway Deregulation

• Registration Number: NCT01789060
• Lead Sponsor: Samsung Medical Center

Brief Summary

PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.

Detailed Description

Recently, among diverse oncogenic signaling pathways, a number of studies have focused on the significance of oncogenic PI3K/AKT (phophatidylinositol 3-kinase/serine-threonine kinase, also known as protein kinase B \[PKB\]) pathway. PI3K(phosphatidylinositol 3-kinase)/AKT pathway phosphorylates and activates AKT as phosphorylated AKT (p-AKT) and plays a critical role promoting malignant phenotype and has prognostic significance in various solid cancers.

However, a systematic approach on the impact of p-AKT overexpression on clinical outcomes has not been performed in malignant lymphoma.

Study Timeline

• Study Start: 2012-12
• Status Verified: 2013-02
• Primary Completion: 2013-02
• Study Completion: 2013-02
• Study First Submitted: 2013-02-07
• Study First Submitted QC: 2013-02-07
• Last Update Submitted: 2013-02-07
• Study First Posted: 2013-02-11
• Last Update Posted: 2013-02-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 262

Inclusion Criteria

1. the patients were pathologically confirmed of malignant lymphoma, according to the World Health Organization classification;
2. the patients had adequate paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT.

Exclusion Criteria

1. Primary central nervous system lymphoma was excluded in this study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Difference of overall survival according to p-AKT status in malignant lymphoma	study entry

Secondary Outcome Measures

Name	Time	Method
Subgroup analysis of overall survival according to histologic subtypes (GCB vs non GCB)	study entry

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of